Gene expression profiles in clinically T1-2N0 ER+HER2− breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed
Open Access
- 5 October 2023
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 203 (1) , 103-110
Abstract
Purpose: Omitting sentinel lymph node biopsy (SLNB) in breast cancer treatment results in patients with unknown positive nodal status and potential risk for systemic undertreatment. This study aimed to investigate whether gene expression profiles (GEPs) can lower this risk in cT1-2N0 ER+ HER2– breast cancer patients treated with BCT. Methods: Patients were included if diagnosed between 2011 and 2017 with cT1-2N0 ER+ HER2– breast cancer, treated with BCT and SLNB, and in whom GEP was applied. Adjuvant chemotherapy recommendations based on clinical risk status (Dutch breast cancer guideline of 2020 versus PREDICT v2.1) with and without knowledge on SLNB outcome were compared to GEP outcome. We examined missing adjuvant chemotherapy indications, and the number of GEPs needed to identify one patient at risk for systemic undertreatment. Results: Of 3585 patients, 2863 (79.9%) had pN0 and 722 (20.1%) pN + disease. Chemotherapy was recommended in 1354 (37.8% guideline-2020) and 1888 patients (52.7% PREDICT). Eliminating SLNB outcome (n = 722) resulted in omission of chemotherapy recommendation in 475 (35.1% guideline-2020) and 412 patients (21.8% PREDICT). GEP revealed genomic high risk in 126 (26.5% guideline-2020) and 82 patients (19.9% PREDICT) in case of omitted chemotherapy recommendation in the absence of SLNB. Extrapolated to the whole group, this concerns 3.5% and 2.3%, respectively, resulting in the need for 28–44 GEPs to identify one patient at risk for systemic undertreatment. Conclusion: If no SLNB is performed, clinical risk status according to the guideline of 2020 and PREDICT predicts a very low risk for systemic undertreatment. The number of GEPs needed to identify one patient at risk for undertreatment does not justify its standard use.Keywords
This publication has 22 references indexed in Scilit:
- A 21-Gene Expression Assay in Breast CancerNew England Journal of Medicine, 2016
- Prospective Validation of a 21-Gene Expression Assay in Breast CancerNew England Journal of Medicine, 2015
- The impact of the pathological lymph node status on adjuvant systemic treatment recommendations in clinically node negative breast cancer patientsBreast Cancer Research and Treatment, 2014
- Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trialThe Lancet Oncology, 2013
- Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: entinel node vs bservation after axillary ltraSou )The Breast, 2012
- A population-based validation of the prognostic model PREDICT for early breast cancerEuropean Journal of Surgical Oncology, 2011
- Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node MetastasisJAMA, 2011
- Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node MetastasesAnnals of Surgery, 2010
- PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancerBreast Cancer Research, 2010
- The MINDACT trial: The first prospective clinical validation of a genomic toolMolecular Oncology, 2007